Comparative Pharmacology
Head-to-head clinical analysis: DAPIPRAZOLE HYDROCHLORIDE versus QUETIAPINE FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPIPRAZOLE HYDROCHLORIDE versus QUETIAPINE FUMARATE.
DAPIPRAZOLE HYDROCHLORIDE vs QUETIAPINE FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dapiprazole is a selective alpha-1 adrenergic receptor antagonist. It blocks alpha-1 receptors on the smooth muscle of the iris dilator muscle, causing miosis (pupil constriction).
Antagonist at serotonin 5-HT2A, dopamine D2, histamine H1, alpha1-adrenergic, and muscarinic M1 receptors. Also partial agonist at serotonin 5-HT1A and dopamine D2 receptors (depending on dose).
5 mg orally once daily, titrated as needed up to 10 mg once daily.
Immediate release: 25-100 mg orally twice daily, titrated as needed up to 400-800 mg/day divided twice daily. Extended release: 50-200 mg orally once daily, titrated up to 400-800 mg/day once daily.
None Documented
None Documented
Terminal elimination half-life is 78 hours; requires dose adjustment in renal impairment
Terminal elimination half-life is approximately 6-7 hours (quetiapine) and 9-12 hours for the active metabolite norquetiapine; with extended-release formulation, effective half-life is ~7 hours due to slower absorption. Clinical steady-state achieved within 2 days.
Primarily renal (80-90% as unchanged drug and metabolites); fecal (10-20%)
Renal: 73% (20% unchanged, remainder as metabolites); Fecal: 21%; Approximately 5% excreted in feces as unchanged drug.
Category C
Category A/B
Atypical Antipsychotic
Atypical Antipsychotic